← RELMADA THERAPEUTICS, INC. (RLMD) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
RELMADA THERAPEUTICS, INC. (RLMD)
Pharmaceutical Preparations · market cap $420M · as of 2026-07-21
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-11-12 (est.)
Earnings
Pipeline
2
programs
Upcoming events
1
next 90d+
Dossier
Ready
cached
Relmada Therapeutics (RLMD) is a clinical-stage pharmaceutical company whose lead asset, REL-1017, is in Phase 3 development for Major Depressive Disorder. With only $9.8M in cash and a runway of approximately 1.9 months as of mid-2026, the company faces an acute liquidity crisis that dominates the near-term investment calculus. A second pipeline asset, NDV01, is in Phase 2 for non-muscle-invasive bladder cancer.
The catalyst path
- 2026-11-12 (est.)Earningsimp 5/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| REL-1017 | Phase 3 | Depressive Disorder, Major |
| NDV01 intravesical controlled release formulation of gemcitabine and docetaxel | Phase 2 | Non Muscle Invasive Bladder Cancer |
Price & technical context
3-month
-42.7%
6-month
-48.1%
12-month
+68.1%
52-wk range
$1.93–$7.86
vs 50-day MA
-19.8%
vs 200-day MA
-33.5%
Realized vol
90.8%
Max drawdown
-93.1%
Daily closes through 2026-10-02. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for RLMD (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 2 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.